Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Uveal melanoma, drawn from the whole corpus: 21 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Half of patients metastasise with no adjuvant therapy despite accurate prediction.
Nothing recorded yet.
Background: Organ tropism: seed and soil. Also on OnCo: Atlas of advanced disease · How cancer spreads: the metastasis stages.
Tebentafusp only for HLA-A*02:01 (about 45% of white patients, fewer elsewhere) and gives few objective responses despite OS benefit.
Liver-tropic metastasis biology poorly understood.
Nothing recorded yet.
Background: Organ tropism: seed and soil. Also on OnCo: Atlas of advanced disease · How cancer spreads: the metastasis stages.
Vision-preserving local therapy still causes radiation retinopathy.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 13 changes by month →When this page itself was last checked or edited.
Objective response rate 36.
Uveal melanoma with unresectable hepatic metastases via hepatic delivery system (Hepzato Kit)
Uveal melanoma with unresectable hepatic metastases affecting less than half the liver and no or limited extrahepatic disease
A milestone in how this cancer is treated.
HLA-A*02:01+ unresectable or metastatic uveal melanoma: first TCR therapeutic approved